Pharmaceutical Technology on MSN14d
AstraZeneca and Alteogen agree on ALT-B4 platform tech"AstraZeneca and Alteogen agree on ALT-B4 platform tech" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site ...
Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase using Hybrozyme platform technology.
AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...
The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
AstraZeneca (AZN) and Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform ...
Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...
The Chosun Ilbo on MSN13d
S. Korea's biotech sector kicks off 2025 with multi-billion-dollar dealsS. Koreas biotech sector kicks off 2025 with multi-billion-dollar deals K-Bio firms secure nearly $2.3 billion in licensing ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback